drugset / Trial / NCT00857259
The Efficacy of Oral Everolimus in Patients With Neovascular Age-related Macular Degeneration
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The study will assess the safety and efficacy of Everolimus (RAD001) alone or in combination with Lucentis in patients with neo-vascular age related macular degeneration (AMD)
Timeline
- Start
- 2009-02
- Primary completion
- 2010-07
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Everolimus | Small molecule | 5 mg | Oral |
| Comparator | Ranibizumab | Monoclonal antibody | 0.5 mg | Intravitreal |